Outlining a five-year biomedical plan, China wants to expand its global role beyond just pipeline innovation.
The biosimilar candidate is intended to reference Hemlibra (emicizumab), which addresses haemophilia A, a genetic disorder. Credit: angellodeco/Shutterstock.com ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results